News

AbbVie and Immunome, Inc. announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor…
Read More...

Moderna, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's…
Read More...

Moderna, Inc. and OriCiro Genomics K.K. announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million. "With this acquisition, we…
Read More...

Orbit Discovery Limited (Orbit) announced it has entered into a Master Service Agreement with SanegeneBio Inc., (Sanegene), a start-up company dedicated to developing novel RNAi-based…
Read More...

Shanghai Xianbo Biotech Co., Ltd., also known as Simnova outside of China, an affiliate of Simcere Investment Group and a clinical-stage biotechnology company developing proprietary…
Read More...

AmerisourceBergen Corporation announced the completion of its acquisition of PharmaLex Holding GmbH. The acquisition of PharmaLex enhances AmerisourceBergen’s growth strategy by…
Read More...

Alpha Healthcare Acquisition Corp. III, a special purpose acquisition company led by Mr. Rajiv Shukla, announced the execution of a definitive business combination agreement with…
Read More...

Capsida Biotherapeutics Inc. announced a multi-year strategic collaboration with Prevail Therapeutics ("Prevail"), a wholly owned subsidiary of Eli Lilly and Company ("Lilly"), to…
Read More...

Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, announced a multi-year collaboration with…
Read More...

WuXi Biologics announced a license agreement with GSK plc under which GSK will have exclusive licenses for up to four bi- & multi-specific TCE antibodies developed using WuXi…
Read More...

Transcenta Holding Limited, a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based…
Read More...

MaxCyte, Inc. announced the signing of a strategic platform license (SPL) with Catamaran Bio, Inc., a biotechnology company developing novel, off the-shelf chimeric antigen receptor…
Read More...

Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. (EVOQ) announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid…
Read More...

Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, and Abiosciences, the single-cell bioinformatics leader, announced a new partnership to co-develop…
Read More...

Alteogen Inc. announced that the company has entered into an exclusive license agreement with Sandoz AG. Under the terms of the agreement, Sandoz will acquire the world-wide rights to…
Read More...

Alligator Bioscience announces an expansion to its research collaboration and license agreement with Orion Corporation, a global pharmaceutical company based in Finland, to discover and…
Read More...

Merck announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover novel antibody-drug conjugates…
Read More...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces a new exclusive licensing and commercialization agreement with Junshi Biosciences, an…
Read More...

Ablaze Pharmaceuticals announced the initiation of a development and manufacturing services agreement with Yonghe Pharmaceutical Technology Co., Ltd. to develop series of targeted…
Read More...

Kala Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for the company’s lead product…
Read More...